Asia-Pacific markets fall as investors parse Moody’s U.S. downgrade

Asia-Pacific markets fall as investors parse Moody’s U.S. downgrade


A man walks past buildings at Central Business District (CBD) in Beijing, China April 8, 2025. 

Tingshu Wang | Reuters

Asia-Pacific markets fell Monday as investors await a slew of economic data from across the region and parse Moody’s downgrade of the U.S. credit rating.

Japan’s benchmark Nikkei 225 slipped 0.54% at the open while the Topix lost 0.36%. South Korea’s Kospi declined 0.47% and the small-cap Kosdaq traded 0.77% lower.

Australia’s benchmark S&P/ASX 200 was down 0.15% at the open.

Futures for Hong Kong’s Hang Seng index stood at 23,270, lower than its last close of 23,345.05.

China is scheduled to release a slate of economic data for April, including housing prices and industrial production.

Thailand is set to report its first-quarter GDP later in the day. The Reserve Bank of Australia will also kickstart its two-day meeting.

On Friday, Moody’s Ratings downgraded the U.S. sovereign credit rating by one level from Aaa to Aa1, citing mounting challenges in funding the federal budget deficit and the increasing cost of refinancing debt in a high-interest-rate environment.

With this downgrade, Moody’s has joined the ranks of other major rating agencies. S&P made the first move in 2011, and Fitch followed suit in 2023, both reducing the U.S. rating to AA+.

Moody’s latest rating downgrade on its own may not cause a big sell-off in U.S. stock and bond markets as seen from the 2011 and 2023 rating downgrades, Vasu Menon, OCBC’s managing director of the investment strategy team said in a note.

“It does however reinforce concerns about the growing U.S. budget deficit and debt, but these are not new and have been discussed extensively for the past few months, and even years,” he noted.

U.S. stock futures declined after the S&P 500 posted a four-day rally on the back of U.S. and China’s temporary tariff cuts and encouraging inflation reports. Futures tied to the Dow Jones Industrial Average dropped 292 points, or 0.7%. S&P 500 futures slipped 0.7%, while Nasdaq 100 futures fell 0.8%.

Overnight stateside on Friday the three major averages closed mixed. The S&P 500 rose for a fifth session and posted a sharp weekly gain, as investors looked past the release of disappointing consumer sentiment data and persistent inflation worry.

The broad market index climbed 0.70% to end at 5,958.38, while the Nasdaq Composite gained 0.52% to close at 19,211.10. The Dow Jones Industrial Average gained 331.99 points, or 0.78%, settling at 42,654.74. Friday’s advance put the 30-stock benchmark into positive territory for 2025.

— CNBC’s Brian Evans, Pia Singh and Tanaya Macheel contributed to this report.



Source

Google joins Microsoft in telling users Anthropic is still available outside defense projects
World

Google joins Microsoft in telling users Anthropic is still available outside defense projects

Google CEO Sundar Pichai gestures to the crowd during Google’s annual I/O developers conference in Mountain View, California, on May 20, 2025. David Paul Morris | Bloomberg | Getty Images Google said it will continue offering Anthropic’s artificial intelligence technology for clients, excluding for defense work, a day after Microsoft issued a similar statement to […]

Read More
Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide
World

Market turmoil is hitting most traditional safe havens. UBS says this is the place to hide

The U.S. and Israel are showing signs of escalating their war against Iran – a move that could batter a variety of assets, even traditional safe havens. To protect their portfolios, investors can snap up stocks from an oft-shorted sector: pharmaceuticals, UBS analysts say. Since the first strikes last Saturday, the Iran War has roiled […]

Read More
Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’
World

Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’

Wegovy is produced by pharmaceutical company Novo Nordisk and has been approved for specifically for chronic weight management in adults and adolescents. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images The chief executive of drugmaker Zealand Pharma sought to calm investors about the latest […]

Read More